Genitourinary Cancers | Specialty

Oral HDAC Inhibitor Improves Antitumor Activity of IL-2 in mRCC

January 11th 2016

A selective class I oral histone deactylase inhibitor may increase the antitumor effect of high- dose interleukin-2 in renal cell carcinoma.

Nivolumab's Survival Benefit Sustained Across RCC Subgroups

January 11th 2016

Nivolumab’s second-line survival benefit in renal cell carcinoma was consistent across subgroups categorized by patient risk status, prior treatment, and degree of metastases, according to an update of the phase III CheckMate-025 trial.

Atezolizumab Update Affirms Activity in Bladder Cancer

January 9th 2016

Second-line treatment with atezolizumab (MPDL3280A) led to durable responses in patients with locally advanced or metastatic urothelial carcinoma.

First Checkpoint/Chemo Combo Study for Urothelial Cancer Falls Short

January 9th 2016

The addition of the CTLA-4 inhibitor ipilimumab to cisplatin and gemcitabine did not significantly improve overall survival for patients with metastatic urothelial cancer.

Avelumab Spurs Responses in Refractory Metastatic Urothelial Cancer

January 9th 2016

The investigational anti-PD-L1 antibody avelumab demonstrated antitumor activity with an acceptable safety profile in a phase Ib trial of patients with metastatic urothelial cancer refractory to standard therapy.

Dr. Elizabeth Plimack on Immunotherapy Potential in Bladder Cancer

January 9th 2016

Elizabeth Plimack, MD, MS, Associate Professor, Director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses immunotherapy in bladder cancer.

Dr. Choueiri on Significance of CheckMate-025 Study for RCC

January 8th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the significance of the CheckMate-025 for renal cell carcinoma.

Dr. Siefker-Radtke on Advancements in Small Cell Urothelial Cancer

January 8th 2016

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses treatment advancements in small cell urothelial cancer.

Expert Predicts PD-1/PD-L1 Agents as Backbone of Combination Therapy in RCC

January 6th 2016

PD-1 and PD-L1 inhibitors, including nivolumab, atezolizumab, and avelumab, will likely play a major role as the backbone of combination therapy for patients with renal cell carcinoma (RCC).

Cabozantinib Improves PFS Across High-Risk RCC Subgroups

January 4th 2016

Cabozantinib significantly improved progression-free survival versus everolimus in patients with renal cell carcinoma regardless of the degree of metastases, type or number of prior treatments, or patient risk status.

ESMO Asia Congress, Alcohol-Free Docetaxel Approved, and More

December 31st 2015

Exelixis Completes Rolling Submission for Cabozantinib in RCC

December 23rd 2015

A new drug application has been submitted for cabozantinib as a treatment for patients with advanced renal cell carcinoma who have received one prior therapy.

Dr. Figlin on Advice for Oncologists Treating RCC

December 22nd 2015

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, provides advice to community oncologists who are treating patients with renal cell carcinoma.

Lenvatinib in Metastatic Renal Cell Carcinoma

December 19th 2015

PD-1 Inhibition in Metastatic Renal Cell Carcinoma

December 19th 2015

Perspectives on Sequencing in Metastatic RCC

December 19th 2015

Goals in Relapsed/Refractory Metastatic RCC

December 19th 2015

mTOR Inhibition for Poor-Risk RCC

December 19th 2015

Frontline Therapy Selection in Metastatic RCC

December 19th 2015

Frontline TKI Selection in Metastatic RCC

December 19th 2015